| Name | Title | Contact Details |
|---|
Equiscript helps safety net providers better understand and grow their 340B pharmacy business. With a keen eye for detail, our skilled people assist our clients in the design and implementation of a home delivery pharmacy program intended to improve health outcomes by putting much-needed medicines into the hands of those patients in the communities we serve.
We are a specialty pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. We focus on developing treatments for GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden. Our management team and board of directors are comprised of professionals with extensive backgrounds in drug research and development, commercialization, finance and business development for leading global pharmaceutical companies and growth-stage biopharmaceutical companies. Our scientific advisory board consists of well-known gastroenterologists and clinical thought leaders. Today, our pipeline consists of two unique clinical stage therapies with the potential to bring benefit to millions of patients with chronic and debilitating GI disorders that are not adequately controlled.
ViiV Healthcare is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products designed to improve quality of care and address unmet medical needs. With a focus on underserved niche markets, including hospital acute care and gastroenterology, we deliver products that serve patients in the U.S. market. Cumberland also makes its products available to patients internationally through select strategic partnerships. We own the worldwide rights to all our brands. While Cumberland`s commercial capabilities are focused on the U.S. market, our business development team is actively pursuing opportunities to make our brands available to patients in markets around the globe. Our primary mission is to improve upon patient care with products that offer clear advantages over existing treatments. We also strive to deliver solutions that may help reduce costs for healthcare providers and, ultimately, patients.
Aeon Biopharma is leading the way as the first and only company focused solely on toxins for therapeutic applications. We are innovating toxin use to improve the lives of patients who are suffering from debilitating medical disorders. AEON is excited to introduce ABP450, the first 900 kDa toxin innovation in the US for over 30 years, and is proud to partner with physicians to advance treatment options. We are dedicated to enhancing patient lives by leading in new ways to use toxins while improving existing toxin therapy.